Input parameters
| Model input | Base-case value | Range | Distribution | Source |
| Outcomes at initial 3 months with r-tPA | ||||
| mRS 0 | 0.213 | 0–1 | Dirichlet | Thomalla et al15 |
| mRS 1 | 0.323 | |||
| mRS 2 | 0.213 | |||
| mRS 3 | 0.122 | |||
| mRS 4 | 0.071 | |||
| mRS 5 | 0.020 | |||
| mRS 6 | 0.039 | |||
| Outcomes at initial 3 months with placebo | ||||
| mRS 0 | 0.149 | 0–1 | Dirichlet | Thomalla et al15 |
| mRS 1 | 0.269 | |||
| mRS 2 | 0.229 | |||
| mRS 3 | 0.169 | |||
| mRS 4 | 0.133 | |||
| mRS 5 | 0.040 | |||
| mRS 6 | 0.012 | |||
| Probability of ICH with r-tPA | 0.020 | 0.009–0.046 | Beta | Thomalla et al15 |
| Probability of ICH with placebo | 0.004 | 0.001–0.023 | Beta | Thomalla et al15 |
| Probability of recurrent stroke in China | 0.118 | 0.112–0.124 | Beta | Pan et al8 |
| Probability of death after recurrent stroke in China | 0.210 | 0.189–0.232 | Beta | Pan et al8 |
| Probability of recurrent stroke in the USA | 0.050 | 0.040–0.060 | Beta | Hong et al17 |
| Probability of death after recurrent stroke in the USA | 0.190 | 0.100–0.300 | Beta | Fagan et al20 |
| Death HRs | ||||
| mRS 0 | 1 | 1–1.2 | Lognormal | Samsa et al23 |
| mRS 1 | 1 | 1–1.2 | ||
| mRS 2 | 1.11 | 0.89–1.3 | ||
| mRS 3 | 1.27 | 1.02–1.52 | ||
| mRS 4 | 1.71 | 1.37–2.05 | ||
| mRS 5 | 2.37 | 1.90–2.84 | ||
| Cost in the US ($) | ||||
| MRI | 816 | ± 25% | Gamma | 26 |
| Additional cost of r-tPA treatment | 8619 | 4309–12928 | Gamma | Leppert et al9 |
| Acute stroke (mRS 0–3) | 9268 | 4633–13901 | Gamma | Earnshaw et al27 |
| Acute stroke (mRS 4–5) | 14 115 | 7057–21171 | Gamma | Earnshaw et al27 |
| Acute stroke (death) | 16 457 | 8228–24685 | Gamma | Earnshaw et al27 |
| ICH | 3399 | 2719–4079 | Gamma | Earnshaw et al27 |
| Annual posthospitalisation (mRS 0–3) | 8157 | 4078–12 235 | Gamma | Earnshaw et al27 |
| Annual posthospitalisation (mRS 4–5) | 22 139 | 11 070–33209 | Gamma | Earnshaw et al27 |
| Recurrent stroke | 25 143 | 12572–37 715 | Gamma | Leppert et al9 |
| Cost in China (¥) | ||||
| MRI | 600 | ±25% | Gamma | Chen et al25 |
| Additional cost of r-tPA treatment | 13 886 | 10 751–16 194 | Gamma | Pan et al8 |
| Acute stroke (mRS 0–1) | 12 214 | 7055–15 379 | Gamma | Pan et al8 |
| Acute stroke (mRS 2–5) | 16 149 | 8875–21 177 | Gamma | Pan et al8 |
| Acute stroke (death) | 13 840 | 6503–18 293 | Gamma | Pan et al8 |
| ICH | 2949 | 641–6155 | Gamma | Pan et al8 |
| Annual posthospitalisation (mRS 0–1) | 8684 | 2600–11 077 | Gamma | Pan et al8 |
| Annual posthospitalisation (mRS 2–5) | 13 213 | 3323–16616 | Gamma | Pan et al8 |
| Recurrent stroke | 18 000 | ± 25% | Gamma | Institutional database |
| Utility | ||||
| mRS 0 | 0.80 | 0.64–1 | Beta | Samsa et al23 |
| mRS 1 | 0.80 | 0.64–1 | ||
| mRS 2 | 0.65 | 0.52–0.78 | ||
| mRS 3 | 0.50 | 0.4–0.6 | ||
| mRS 4 | 0.35 | 0.28–0.42 | ||
| mRS 5 | 0.20 | 0.16–0.24 | ||
| Death | 0.00 | NA | NA | NA |
| Disutility of ICH | 0.38 | 0.30–0.46 | Normal | Christensen et al30 |
| Discount rate | 0.03 | 0–0.08 | Beta | Sanders et al31 |
NA: not available; mRS: modified Rankin Scale; ICH, intracranial haemorrhage; r-tPA, recombinant tissue-type plasminogen activator.